The delayed diagnosis of diabetes leads to prolonged periods of uncontrolled hyperglycemia, resulting in severe diabetesrelated complications, such as diabetic retinopathy (eye problems), diabetic foot ulcers (DFU), diabetic nephropathy (kidney problems), and cardiovascular diseases.
The vast number of people affected by diabetes, including many who are undiagnosed or at risk, presents a massive market for innovative treatments and preventive solutions. New technologies and novel treatment approaches offer hope for better prevention and management of these diabetes-related complications. Let's delve deeper into the efforts to address these complications.
The health complications associated with diabetes pose a mounting burden on healthcare systems. Various studies underscore the elevated risks faced by diabetes patients, particularly concerning kidney, eye, foot, and cardiovascular complications.
A study in Frontiers in Public Health shows a significant rise in the economic burden of diabetes in urban China, with increasing hospitalisation rates and diabetes complications. The study reports nearly 1.4 million deaths and $165.3 billion in diabetes-related health costs, indicating a substantial economic burden.
Australia faces a similar challenge. Data from the Australian Institute of Health and Welfare reveals that approximately $2.5 billion is expended annually on diabetes management. Moreover, diabetes plays a pivotal role in exacerbating the economic toll of other prevalent conditions, such as heart disease (costing $2 billion per year), chronic kidney disease ($1.7 billion per year), and stroke ($660 million per year). Collectively, these issues impose a substantial combined annual expense of $6.86 billion on the Australian healthcare system.
Esta historia es de la edición November 2023 de BioSpectrum Asia.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición November 2023 de BioSpectrum Asia.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor? Conectar
Australia invests $1.89B for health and medical research transformation
The government is investing in a once in a generation transformation of health and medical research in Australia.
NZ suggests new way to prevent rheumatic heart disease progression
A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.
WHO prequalifies Takeda's dengue vaccine
A new vaccine for dengue has received prequalification from the World Health Organization (WHO).
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.
HOYA Group to distribute AIassisted lesion detection device in US
Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.
Saudi Arabia pledges $500M to protect children from polio
At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.
How Thai Biotech is Thriving with Innovations
Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.
Why multi-use real estate is in demand for life sciences companies
India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.
